News
Truist Securities Reiterates Buy on Tourmaline Bio, Maintains $74 Price Target
25 Mar 24
News, Price Target, Reiteration, Analyst Ratings
Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
21 Mar 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
12 Health Care Stocks Moving In Thursday's Intraday Session
21 Mar 24
Movers
Dow Jumps 200 Points; US Weekly Jobless Claims Fall
21 Mar 24
Earnings, News, Penny Stocks, Eurozone, Commodities, Small Cap, Global, Intraday Update, Markets, Trading Ideas
12 Health Care Stocks Moving In Thursday's Pre-Market Session
21 Mar 24
Movers
Five Below Posts Q4 Results, Joins LexinFintech And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
21 Mar 24
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Tourmaline Bio Q4 EPS $(0.81) Up From $(5.51) YoY, Cash Balance of $203.0M
19 Mar 24
Earnings, News
Tourmaline Bio Reports Pricing Of Public Offering Of 4.61M Shares Of Its Common Stock At $32.50 Per Share
25 Jan 24
News, Offerings
Tourmaline Bio Announces Proposed Public Offering Of Common Stock; No Size Or Amount Disclosed
24 Jan 24
News, Offerings
12 Health Care Stocks Moving In Wednesday's After-Market Session
24 Jan 24
Movers
Tourmaline Bio Announces Expected Upcoming Milestones For TOUR006 In Thyroid Eye Disease and Atherosclerotic Cardiovascular Disease; Expects Cash Runway Through 2026
8 Jan 24
Biotech, Earnings, News, Health Care, General
TDCX Receives Preliminary Non-binding Proposal Letter, Joins Pure Storage, Dyne Therapeutics And Other Big Stocks Moving Higher On Wednesday
3 Jan 24
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Press releases
Tourmaline Bio to Present at Upcoming Investor Conferences
27 Feb 24
News, Press Releases
Thinking about buying stock in Digital Brands Group, Tourmaline Bio, Crown Electrokinetics, Datadog, or UiPath?
14 Feb 24
Opinion, Press Releases
Tourmaline Bio Announces Closing of $172.5 Million Public Offering of Common Stock, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
29 Jan 24
Markets, Press Releases
Tourmaline Bio Announces Pricing of Public Offering of Common Stock
25 Jan 24
Press Releases
Tourmaline Bio Announces Proposed Public Offering of Common Stock
24 Jan 24
News, Financing, Press Releases
Tourmaline Bio Announces Expected Upcoming Key Milestones for the Clinical Development of TOUR006, a Long-Acting Subcutaneous Inhibitor of IL-6 with Best-in-Class Potential, in Thyroid Eye Disease (TED) and Atherosclerotic Cardiovascular Disease (ASCVD)
8 Jan 24
Health Care, Press Releases, General